BPC-157 Dosage: What the Dosing Question Answers

Summary: Every BPC-157 dosage figure you find online traces back to animal research or to somebody's arithmetic. Here is how a real dose is built, and why that process has not happened for this compound.

This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before starting, changing, or stopping any medication.

BPC-157 dosage figures are easy to find and hard to source. Almost every number you meet online traces back to a rat study rather than to a human label, and the distance between those two things is wider than it looks.

This article is about that distance. It is not a set of instructions, because nobody is in a position to give you one. It is an explanation of what kind of question the dosing question actually is, and what would have to happen before it had a real answer.

How a number gets onto a label

You already know one version of this process, even if you have never thought of it as a process. Consider semaglutide, which reached patients through a long and well documented route.

It started with animal work, which established that the molecule did something measurable and did not cause obvious harm. Animal amounts were never treated as the answer. They were treated as a place to start.

Then came the first human studies, small groups of volunteers, designed to find out what the body does with the drug and what it tolerates. After that came larger studies built specifically to compare one amount against another in people, with the outcome measured against a control group rather than against how the volunteers felt about it.

Regulators at the FDA and the EMA then read all of it, argued with the company about the interpretation, and eventually agreed on numbers that could be printed on a label. A prescriber picks from those numbers. A pharmacist dispenses against them. If a number later proves wrong for some group of patients, a reporting system exists to catch that and the label gets changed.

Six or seven distinct stages, each one capable of overturning the previous one. The number on the box is the residue of all of them.

Why the BPC-157 dosage figures online are not doses

BPC-157 has not been through that machinery. It has no marketing authorisation from the FDA, the EMA or the MHRA. It is sold as a research chemical, and research chemicals do not have labels, because a label is a regulatory document rather than a printed sticker.

So where do the circulating numbers come from? Usually from one of two places. Either somebody has read a rat study, found the amount given to the animals, and converted it using a body weight ratio. Or somebody has copied a figure from another website that did exactly that, at which point the original source disappears and the number starts to look like consensus.

Read down the right hand column and the pattern is consistent. Every stage that turns an animal number into a human number is missing.

The conversion nobody in a forum thread actually performs

Converting an animal amount into a human one is a real discipline with a real literature behind it. It accounts for differences in metabolic rate, in how quickly the kidneys clear a compound, in body surface area rather than raw weight, and in how much of a substance survives the route it was given by.

That last point matters here more than most people realise. The rat literature on BPC-157 has used delivery routes with no everyday human equivalent, including administration directly into the abdominal cavity and delivery dissolved in the animals' drinking water. A number attached to one of those routes does not transfer to a different route in a different species by multiplying by a weight ratio.

There is also the question of what the number was for. In rat tendon and gut studies, the amount given was chosen to produce a visible effect in that model, not to be the smallest useful amount or the largest safe one. It was a working value inside an experiment, not a recommendation escaping from one.

Notice how conservative the equivalent step is in a normal drug programme. When a compound first reaches human volunteers, the starting amount is deliberately set well below anything the animal work suggested would be active, precisely because the translation is understood to be unreliable. The people best equipped to convert an animal number treat their own conversion as a guess that needs checking. A website that performs the same conversion and presents the result as a protocol is claiming a confidence the field itself does not have.

What the registered human trials will and will not settle

Human trials of BPC-157 do exist, and this is where a lot of writing on the subject goes wrong in one direction or the other. Saying no human trials exist is false. Saying human benefit has been shown is also false.

Two are worth naming. NCT07803250 is a Phase 1 study with 30 participants looking at recovery after rotator cuff repair, listed as not yet recruiting. NCT02637284 is the older Phase 1 safety and pharmacokinetics study with 42 participants, and its status is unknown.

None of them has published efficacy results. When they do, they will have used specific amounts, and those amounts will have been chosen by people with access to the full preclinical package. That is a great deal more than any website has. It is still not a label, because a single trial amount is a hypothesis being tested rather than a conclusion being reported.

What the dosing question is really asking

When someone searches for a BPC-157 dosage, they are usually asking something reasonable: is there a known amount that works and is safe in a person. The honest answer is that the question is ahead of the evidence. The rat work is substantial and much of it comes from a small number of research groups. The human work is registered and unpublished. Between those two facts there is no number that anyone can stand behind.

The BPC-157 dosage question is therefore not hard in the way a difficult calculation is hard. It is unanswered in the way a question nobody has run the study for is unanswered. It helps to notice what the question would look like if it had been answered. There would be a document naming an amount, a frequency, a duration and a population, with a regulator's name at the top and a list of the studies that justify each part of it. You can pull that document up for semaglutide in a few seconds. For BPC-157 there is nothing to pull up, in any country, which is a more informative fact than any individual number.

There is a second question hiding inside the first, which is whether the material in the vial is what the label claims. With an approved medicine, identity and purity are guaranteed by manufacturing rules that regulators inspect. With a research chemical, they are guaranteed by whoever sold it to you. An amount calculated to three decimal places means very little if the contents are uncertain.

One last thing is worth separating out, because it often gets folded into the dosing question by accident. How much to take, how often to take it, and for how long are three different questions, and each is settled by a different kind of study. Frequency depends on how quickly the body clears the compound, which is what a pharmacokinetic study measures. Duration depends on how long the underlying process takes to respond, which needs a controlled trial with follow up. A single number lifted from an animal experiment cannot answer any of the three, and it is usually presented as if it answered all of them at once.

Related reading on this compound: what BPC-157 actually is, why before and after images do not settle it, whether cycling applies here.

Questions readers send in

Is there an official BPC-157 dosage anywhere?

No. No regulator has approved the compound, so no official amount exists in any jurisdiction. Any figure presented as standard is somebody's convention, not an authority's.

Why do so many sources agree on similar numbers?

Agreement between websites is not independent confirmation. Numbers get copied, and a figure repeated across fifty pages can still trace back to one animal study and one person's arithmetic.

Do the rat studies at least give a ballpark?

They give a ballpark for rats, under the specific route and schedule those experiments used. Translating that into a human ballpark is exactly the step that human trials are designed to perform, and it has not been published.

Would an efficacy result give us a dose?

It would give us an amount that was tested, along with what happened. No registered study is at that stage. Turning that into a recommended dose requires more studies and a regulatory review, which is the difference between evidence existing and a medicine existing.

Does the form it comes in change the answer?

It changes the pharmacokinetics, so it changes the question rather than answering it. Oral and injected routes are not interchangeable for peptides in general, and for BPC-157 specifically there is no published human pharmacokinetic data to compare them with.

What is a reasonable position to hold?

That the compound has an interesting animal literature, an unfinished human literature, and no established dose. Those three statements are compatible, and holding all of them at once is more accurate than picking whichever one suits the conclusion you wanted.